GASTROINTESTINAL COMPLICATIONS OF DIABETES MELLITUS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Vascular complications, nephropathy, and neuropathies at different sites are the main cause of death in patients with any type of diabetes mellitus (DM) and closely related to poor hyperglycemia control during treatment. In the presence of insulin resistance and type 2 DM, gastrointestinal complications occur more frequently; furthermore, most patients develop fatty liver disease. The latter, an independent predictor for the progression of DM and its complications, requires detection and treatment in the early stage of the disease.

Full Text

Restricted Access

About the authors

E. Vovk

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Email: kafedrakf@mail.ru
Candidate of Medical Sciences

References

  1. th Edition of the Diabetes Atlas released on World Diabetes Day. Brussels, Belgium: International Diabetes Federation, 2011. Available from: URL:http: /www. idf.org/diabetesatlas/news/fifth-editionrelease
  2. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus // Diabet. Care. - 1997; 20: 1183-97.
  3. Source: 2007-2009 National Health Interview Survey estimates projected to year 2010. http://www.cdc.gov
  4. Source: Diabetes Report Card 2012: National and State Profile of Diabetes and Its Complications. www.cdc.gov/diabetes/pubs
  5. Hunt K., Schuller K. The increasing prevalence of diabetes in pregnancy // Obstet. Gynecol. Clin. North Am. - 2007;34:173-99.
  6. Kitzmiller J., Dang-Kilduff L., Taslimi M. Gestational diabetes after delivery: short-term management and long-term risks // Diabet. Care. - 2007;30:225-35.
  7. Source: Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2011. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2011. http://www.cdc.gov/diabetes/ pubs/pdf
  8. Imperatore G., Cadwell B., Geiss L. et al. Thirty-year trends in cardiovascular risk factor levels among U.S. adults with diabetes // Am. J. Epidemiol. - 2004; 160 (6): 531-9.
  9. Грудянов А.И. Терапия воспалительных заболеваний пародонта снижает риск развития ишемической болезни сердца и осложнений при сахарном диабете // Лечащий врач. - 2012; 7.
  10. Рединова Т.Л., Злобина O.A., Мерзлякова О.Г. Состояние полости рта у больных сахарным диабетом. Современные вопросы стоматологии: Мат-лы 12-ой межрегион. научно-практ. конф. стоматологов. Ижевская гос. мед. акад. Ижевск, 2000; 148-52.
  11. Токмакова С.И., Бондаренко О.В., Сысоева О.В. Влияние возраста и обменных нарушений при сахарном диабете на слизистую оболочку полости рта. Стоматология. Рос. науч. форум с междунар. участием «Стоматология на пороге третьего тысячелетия», 6-9 февраля 2001 г. МГМСУ. М., 2001; 117-8.
  12. Stender S., Schuster H., Barter R. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goats and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trail // Diab., Obes. Metab. - 2005; 7 (4): 430-8.
  13. Bytzer P., Talley N., Leemon M. et al. Prevalence of Gastrointestinal Symptoms Associated With Diabetes MellitusA Population-Based Survey of 15 000 Adults // Arch. Intern. Med. - 2001; 161 (16): 1989-96.
  14. Gustafsson R., Littorin B., Berntorp K. et al. Esophageal dysmotility is more common than gastroparesis in diabetes mellitus and is associated with retinopathy // Rev. Diabet. Stud. - 2011; 8: 268-75.
  15. Wang X., Pitchumoni C., Chandrarana K. et al. Increased prevalence of symptoms of gastroesophageal reflux diseases in type 2 diabetics with neuropathy // World J. Gastroenterol. - 2008; 14: 709-12.
  16. Lee S., Keum B., Chun H. et al. Gastroesophageal Reflux Disease in Type II Diabetes Mellitus With or Without Peripheral Neuropathy // J. Neurogastroenterol. Motil. - 2011; 17: 274-8.
  17. Lluch I., Ascaso J., Mora F. et al. Gastroesophageal reflux in diabetes mellitus // Am. J. Gastroenterol. - 1999; 94: 919-24.
  18. Lauffer A., Forcelini C., Ruas L. et al. Gastroesophageal reflux disease is inversely related with glycemic control in morbidly obese patients // Obes. Surg. -2011; 21:864-70.
  19. Choung R., Locke G., Schleck C. et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population // Am. J. Gastroenterol. - 2012; 107: 82-8.
  20. Rayner C., Samsom M., Jones K. et al. Relationships of upper gastrointestinal motor and sensory function with glycemic control // Diabet. Care. - 2001; 24: 371-81.
  21. Boaz M., Kislov J., Dickman R. et al. Obesity and symptoms suggestive of gastroparesis in patients with type 2 diabetes and neuropathy // J. Diabet. Complications. - 2001; 25: 325-8.
  22. Kim J., Park S., Ko S. et al. Diabetic factors associated with gastrointestinal symptoms in patients with type 2 diabetes // World J. Gastroenterol. - 2010; 16 (14): 1782-7.
  23. Bagyanszki М., Bódi N. Diabetes-related alterations in the enteric nervous system and its micro environment // W. J. Diabetes. - 2012; 3 (5): 80-93.
  24. Tang D., Friedenberg F. Gastroparesis: approach, diagnosticevaluation, and management // Dis. Mon. - 2011; 57: 74-101.
  25. Хворостинка В.Н., Кривоносова Е.М. Патогенетические особенности состояния гастродуоденальной системы у больных сахарным диабетом // Врачеб. практ. - 2004; 3: 9-13.
  26. Kashyap P, Farrugia G. Oxidative stress: key player in gastrointestinal complications of diabetes // Neurogastroenterol. Motil. - 2011; 23: 111-4.
  27. Izbéki F., Wittman T., Rosztóczy A. et al. Immediate insulin treatment prevents gut motility alterations and loss of nitrergic neurons in the ileum and colon of rats with streptozotocin-induced diabetes // Diabet. Res. Clin. Pract. -2008; 80: 192-8.
  28. Sanders K., Ördög T., Koh S. et al. A Novel Pacemaker Mechanism Drives Gastrointestinal Rhythmicity // News Physiol. Sci. - 2000; 15: 291-8.
  29. Ordög T., Takayama I., Cheung W. et al. KM. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis // Diabetes. -2000; 49: 1731-9.
  30. Grover M., Farrugia G., Lurken M. et al. Cellular changes in diabetic and idiopathic gastroparesis // Gastroenterology. - 2011; 140: 1575-85.
  31. De Giorgio R., Giancola F., Boschetti E. et al. Enteric glia and neuroprotection: basic and clinical aspects // Am. J. Physiol. Gastrointest. LiverPhysiol. -2012;303(8):887-93.
  32. Vanormelingen C., Tack J., Andrews C. Diabetic gastroparesis // Br. Med. Bull. - 2013;105:213-30.
  33. Hammer J., Howell S., Bytzer P. et al. Symptom clustering in subjects with and without diabetes mellitus: a population-based study of 15,000 Australian adults // Am. J. Gastroenterol. - 2003; 98 (2): 391-8.
  34. Hasler W. Gastroparesis: pathogenesis, diagnosis and management // Nat. Rev. Gastroenterol. Hepatol. - 2011;8:438-53.
  35. Hasler W. Gastroparesis // Curr. Opin. Gastroenterol. - 2012; 28: 621-8.
  36. Stevens J., Jones K., Rayner C. et al. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives // Expert Opin. Pharmacother. -2013; 14 (9): 1171-86.
  37. Krishnan B., Babu S., Walker J. et al. Gastrointestinal complications of diabetes mellitus // W. J. Diabetes. - 2013; 4 (3): 51-63.
  38. Chandrasekharan B., Anitha M., Blatt R. et al. Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress // Neurogastroenterol. Motil. - 2011; 23 (2): 131-8.
  39. Harrison's Principles of Internal Medicine, 17th ed. New York: McGraw-Hill Medical Publishing Division.
  40. Chalasani N., Younossi Z., Lavine J. et al. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association // Hepatology. - 2012; 55 (6): 2005-23.
  41. Bellentani S., Scaglioli F., Marino M. et al. Epidemiology of non-alcoholic fatty liver disease // Dig. Dis. - 2010; 28: 155-61.
  42. Гастроэнтерология. Нац. руководство. Под ред. В.Т. Ивашкина, Т.Л. Лапина / М.: ГЭОТАР-Медиа, 2008; с. 626-32.
  43. Suzuki A., Angulo P., Lymp J. et al. Chronological development of elevated aminotransferases in a nonalcoholic population // Hepatology. - 2005; 41 (1): 64-71.
  44. Hamaguchi M., Kojima T., Takeda N. et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease // Ann. Intern. Med. -2005;143(10):722-8.
  45. Whalley S., Puvanachandra P., Desai A. et al. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs // Clin. Med. - 2007; 7 (2): 119-24.
  46. Lee J., Kim K., Lee S. et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center // J. Hepatol. - 2007; 47 (2): 239-44.
  47. Marcos A., Fischer R., Ham J. et al. Selection and outcome of living donors for adult to adult right lobe transplantation // Transplantation. - 2000; 69: 2410-5.
  48. Маев И.В., Дичева Д.Т., Лебедева Е.Г. и др. Роль эссенциальных фосфолипидов в современных схемах лечения неалкогольного стеатогепатита // Гастроэнтерология (Прил. Consilium Medicum). - 2011; 1: 34-7.
  49. Bellentani S., Pozzato G. et al. Clinical course and risk factors of hepatitis C virus related disease in the general population: report from the Dionysos study // Gut. - 1999; 44 (3): 874-80.
  50. Williams C., Stenger J., Asike M. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study // Gastroenterology. -2011; 140: 124-31.
  51. Vernon G., Baranova A., Younossi Z. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults // Aliment. Pharmacol. Ther. - 2011; 34: 274-85.
  52. Цуканов В., Тонких Ю., Каспаров Э. Неалкогольная жировая болезнь печени у взрослого городского населения России (распространенность и факторы риска) // Врач. - 2010; 9: 2-4.
  53. Драпкина О., Смирин В., Ивашкин В. Сахарный диабет как фактор риска неалкогольной жировой болезни печени // Врач. - 2010; 3: 7.
  54. Ebert E. Gastrointestinal complications of diabetes mellitus // Dis. Mon. -2005; 51: 620-63.
  55. Farrell G., Larter C. Nonalcoholic fatty liver disease: from steatosis to cirrhosis // Hepatology. - 2006; 43 (2): 99-11.
  56. Das U. Is obesity an inflammatory condition? // Nutrtion. - 2001; 17: 953-66.
  57. Mohanty P., Ghanim H., Hamouda W. et al. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells // Am. J. Clin. Nutr. - 2002; 75: 767-72.
  58. Ricci R. et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis // Science. - 2004; 306: 1558-61.
  59. Wang S., Leonard S., Castranova V. et al. The role of superoxide radical in TNF-alpha induced NF-kappaB activation // Ann. Clin. Lab. Sci. - 1999; 29: 192-9.
  60. Seo J. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression // Mol. Cell. Biol. - 2004; 24: 3430-44.
  61. Carroll M., Schade D. Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers // Circulation. - 2003; 108: 24-31.
  62. Nappo F., Esposito K., Cioffi M. et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals // J. Am. Coll.Cardio. - 2002; l39: 1145-50.
  63. Oostrom A., Sijmonsma T., Verseyden C. et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction // J. Lipid. Res. - 2003; 44: 576-83.
  64. Malhi H., Gores G. Molecular mechanisms of lipotoxicity in Nonalcoholic Fatty Liver Disease // Semin. Liver.Dis. - 2008; 28: 360-9.
  65. Маммаев С.Н., Багомедова Н.В., Богомолов П.О. и др. Цитокиновая система при неалкогольном стеатогепатите // Рос. журн. гастроэнтерол. гепатол. колопроктол. - 2007; 17 (4): 30-5.
  66. Mohanty P., Hamouda W., Garg R. et al. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes // J. Clin. Endocrinol. Metab. - 2000; 85: 2970-3.
  67. Aljada A., Ghanim H., Mohanty P. et al. Glucose intake induces an increase in AP-1 and Egr-1 binding activities and tissue factor and matrix metalloproteinase expressions in mononuclear cells and plasma tissue factor and matrix metalloproteinase concentrations // Am J Clin. Nutr. - 2004; 80: 51-7.
  68. Kaneto H. et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide // Nat. Med. - 2004; 10: 1128-32.
  69. Berger М., Roden М., Sting Н. Elevated serum free fatty acid concentrations inhibit T lymphocyte signaling // The FASEB J. - 2000; 14: 939-47.
  70. Adams L., Lymp J., StSauver J. et al. The natural history of non-alcoholic fatty liver disease: a population-based cohortstudy // Gastroenterology. - 2005; 129: 113-21.
  71. Marschall H., Einarsson C. Gallstone disease // J. Int. Med. - 2007; 261; 529-42.
  72. Hamet P. What matters in ADVANCE and ADVANCE-ON // Diabet. Obes. Metab. - 2012;14 (1): 20-9.
  73. Tandon N., Ali M., Narayan K. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes // Am. J. Cardiovasc. Drugs. - 2012; 12 (1): 7-22.
  74. Du X., Ninomiya T., de Galan B. et al. ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study // Eur. Heart J. - 2009; 30 (9): 1128-35.
  75. Promrat K., Kleiner D., Niemeier H. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis // Hepatology. - 2010; 51: 121-9.
  76. Kidd P. Cell membranes, endothelia, and atherosclerosis - the importance of Phosphatidylcholine // Altern. Med. Rev. - 1996;1:148-67.
  77. Mourad A. et al. Influence of Soy Lecithin Administration on Hypercholesterolemia // Cholesterol. - 2010; Article ID 824813.
  78. Ma X., Zhao J., Lieber C. Polyenylphosphatidylcholine attenuates nonalcoholic hepatic fibrosis and accelerate its regression // J. Hepatol. - 1996; 24: 604-13.
  79. Watanabe A., Kobayashi M., Morishita N. et al. Multimodal treatement resulting in a rapid improvement of fatty liver disease in obese patients // Curr. Ther. Res. - 1988; 43: 239-46.
  80. Kuntz E., Kuntz H. Гепатология. Уч. пособ. и атлас. Изд 3-е / Heidelberg: SpringerPress, 2008; гл. 40, с. 896.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies